查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1738518

全球镰状细胞疾病治疗市场规模（按类型、药物类别、最终用户、区域范围和预测）

Global Sickle Cell Disease Treatment Market Size By Type (Bone Marrow Transplant, Blood Transfusion), By Drug Class (Hydroxyurea, L-glutamine, Voxelotor), By End-User (Hospitals, Specialty Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

镰状细胞疾病治疗市场规模与预测

2024 年镰状细胞疾病治疗市场规模价值 33 亿美元，预计到 2032 年将达到 103 亿美元，在 2026-2032 年预测期内的复合年增长率为 16.85%。

  • 镰状细胞疾病 (SCD) 是一种遗传性血液疾病，其特征是血红蛋白异常，导致红血球呈镰状，阻塞血管并引起疼痛、感染疾病和器官损伤。
  • 镰状细胞性猝死 (SCD) 的治疗包括骨髓移植、输血和药物治疗，以控制症状和预防併发症。骨髓移植是唯一的治疗方法，但由于捐赠者相容性问题，其可用性有限，因此药物治疗对大多数患者来说是必不可少的。
  • 随着基因治疗和根治性治疗方法的进步为长期疾病管理和改善患者预后带来希望，镰状细胞疾病治疗的未来看起来更加光明。

全球镰状细胞疾病治疗市场动态

影响全球镰状细胞疾病治疗市场的关键市场动态是：

关键市场驱动因素

  • 基因治疗的进展：基因治疗的进展：基因治疗的发展透过针对致病基因突变，为治疗镰状细胞疾病带来了巨大的希望。 CRISPR 和其他镰状编辑技术的进步有望彻底改变治疗格局，为患者提供治癒选择。
  • 镰状细胞病患疾病率上升：镰状细胞疾病患者数量正在增加，尤其是在撒哈拉以南非洲、中东和印度的部分地区，这刺激了对有效治疗方法的需求。旨在筛检和早期诊断该疾病的公共卫生措施正在推动市场成长。
  • 政府和非政府组织 (NGO) 的倡议：各国政府和非政府组织不断加强，提供治疗机会、提高公众意识并资助新治疗方法的研究，这些措施正在支持治疗市场的发展。旨在扩大发展中地区骨髓登记和药物治疗可近性的计画也为发展做出了贡献。

主要问题

  • 治疗费用高：骨髓移植和基因治疗等治疗费用昂贵，限制了低收入社区患者获得治疗的机会。此外，SCD 的长期治疗需要定期输血和药物治疗，这进一步增加了患者和医疗保健系统的经济负担。
  • 骨髓移植机会有限：骨髓移植有可能治癒SCD，但找到合适的捐赠者是一项艰鉅的挑战。患者和捐赠者之间需要基因匹配，这限制了骨髓移植的可近性，尤其是在医疗基础设施有限的地区。
  • 开发中地区缺乏认知和医疗保健服务：在低收入地区，许多患者缺乏全面的医疗保健服务，导致诊断和治疗困难。农村地区对SCD的认知度低，导致诊断延误，发病率和死亡率居高不下。

主要趋势

  • 基因治疗和治疗方法：基因治疗的研究和开发正在为SCD的根治性治疗铺平道路。目前，旨在纠正SCD致病基因的临床试验正在进行中，这为依赖终身治疗的患者带来了新的希望。
  • 引入新药疗法：SCD 的药物研发正在取得进展，Voxelotor 和 L-谷氨酰胺等新疗法已核准，可减少疼痛发作的频率并改善血红蛋白水平。这些治疗方法旨在改善 SCD 患者的生活品质。
  • 全球卫生倡议：各国政府、非政府组织和医疗保健组织正在加强全球卫生工作，以改善SCD治疗的可近性，尤其是在疾病负担较高的非洲和印度。这些倡议旨在提高公众意识、筛检和治疗方法。

目录

第 1 章全球镰状细胞疾病治疗市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 全球镰状细胞疾病治疗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

镰状细胞疾病治疗市场（按类型）

  • 概述
  • 骨髓移植
  • 输血

镰状细胞疾病治疗市场（依药物类别）

  • 概述
  • 羟基脲
  • L-麸酰胺酸
  • 沃克塞洛托

镰状细胞疾病治疗市场（依最终使用者）

  • 概述
  • 医院
  • 专科诊所

镰状细胞疾病治疗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 英国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9. 全球镰状细胞疾病治疗市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Global Blood Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Emmaus Life Sciences, Inc.
  • Bluebird Bio, Inc.
  • Sangamo Therapeutics, Inc.
  • CRISPR Therapeutics AG.

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 59424

Sickle Cell Disease Treatment Market Size And Forecast

Sickle Cell Disease Treatment Market size was valued at USD 3.3 Billion in 2024 and is projected to reach USD 10.3 Billion by 2032, growing at a CAGR of 16.85% from 2026 to 2032.

  • Sickle Cell Disease (SCD) is an inherited blood disorder characterized by abnormal hemoglobin, resulting in red blood cells adopting a sickle-like shape. This leads to blockages in blood vessels causing pain, infections, and organ damage.
  • Treatments for SCD include bone marrow transplants, blood transfusions, and drug therapies aimed at managing the symptoms and preventing complications. While bone marrow transplants are the only potential cure, their availability is limited due to donor compatibility issues making drug treatments essential for most patients.
  • The future of SCD treatment is evolving with advancements in gene therapies and curative treatments offering hope for long-term disease management and improved patient outcomes.

Global Sickle Cell Disease Treatment Market Dynamics

The key market dynamics that are shaping the global sickle cell disease treatment market include:

Key Market Drivers:

  • Advancements in Gene Therapy: The development of gene therapies offers significant potential for treating SCD by targeting the genetic mutations that cause the disease. Breakthroughs in CRISPR and other gene-editing technologies are anticipated to revolutionize the treatment landscape providing curative options for patients.
  • Rising Prevalence of Sickle Cell Disease: The growing number of SCD cases, particularly in sub-Saharan Africa, the Middle East, and parts of India is increasing the demand for effective treatment solutions. Public health initiatives aimed at screening and diagnosing the disease early are boosting market growth.
  • Government and Non-Governmental Organization (NGO) Initiatives: Increased efforts by governments and NGOs to provide access to care, improve awareness, and fund research for new therapies are supporting the treatment market. Programs aimed at increasing bone marrow registries and access to drug therapies in developing regions are also contributing to market expansion.

Key Challenges:

  • High Costs of Treatment: Treatments such as bone marrow transplants and gene therapies are expensive limiting their accessibility to patients in lower-income regions. Additionally, long-term management of SCD requires regular blood transfusions and drug therapies, further increasing the economic burden on patients and healthcare systems.
  • Limited Access to Bone Marrow Transplants: While bone marrow transplants offer the potential for curing SCD, finding compatible donors remains a significant challenge. The need for genetic matches between patients and donors restricts the availability of transplants, particularly in regions with limited healthcare infrastructure.
  • Lack of Awareness and Healthcare Access in Developing Regions: In low-income regions, many patients lack access to comprehensive healthcare services, making diagnosis and treatment difficult. Limited awareness of SCD in rural areas results in delayed diagnosis leading to higher morbidity and mortality rates.

Key Trends:

  • Gene Therapy and Curative Approaches: Research and development in gene therapies are paving the way for potentially curative treatments for SCD. Clinical trials are ongoing to determine the efficacy of these therapies in modifying or correcting the faulty gene responsible for SCD offering new hope for patients who currently rely on lifelong treatments.
  • Introduction of New Drug Therapies: Drug development for SCD is progressing, with new therapies such as voxelotor and L-glutamine gaining approval for reducing the frequency of painful crises and improving hemoglobin levels. These therapies are aimed at improving the quality of life for SCD patients.
  • Global Health Initiatives: Governments, NGOs, and healthcare organizations are increasing their focus on global health initiatives to ensure better access to SCD treatments, particularly in Africa and India, where the disease burden is high. These initiatives aim to improve awareness, screening, and treatment availability.

Global Sickle Cell Disease Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global sickle cell disease treatment market

North America:

  • North America dominates the global sickle cell disease treatment market, with the United States holding the largest market share. This is driven by a well-established healthcare infrastructure, advancements in gene therapies, and increased funding for research and development. The U.S. government, through the National Institutes of Health (NIH), has initiated various programs to support SCD treatment research and improve patient care. Additionally, the availability of advanced treatments such as gene therapy and new drug approvals is contributing to market growth.
  • Organizations such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are actively involved in research and awareness campaigns to address the issues presented by SCD. There is also extensive collaboration between pharmaceutical corporations and research institutions to produce more effective medicines such as voxelotor and crizanlizumab which have just received FDA approval. With higher awareness, improved diagnoses, and increased treatment options, the North American market is positioned to expand further meeting the patient population's unmet requirements and enhancing the overall quality of life for those living with sickle cell disease.

Asia Pacific:

  • The Asia-Pacific region is witnessing significant growth in the SCD treatment market driven by increasing awareness of the disease and improving healthcare infrastructure. Countries like India and Pakistan have high incidences of SCD, with public health programs being implemented to improve screening and diagnosis. Government initiatives aimed at increasing access to bone marrow transplants and affordable drug therapies are expected to fuel market growth. Additionally, rising investments in healthcare and partnerships with global health organizations are improving the availability of advanced treatment options in the region.
  • Advances in treatment choices and technologies are changing the SCD treatment landscape in Asia Pacific. Traditional treatments, such as hydroxyurea, blood transfusions, and pain management medicines are being supplemented with new therapies, such as gene therapy and developing biologics with the potential to greatly enhance quality of life. Clinical trials for novel medicines are gaining traction, as pharmaceutical companies engage in R&D to bring viable cures to market. Furthermore, public-private partnerships and collaborations encourage the delivery of vital pharmaceuticals and access to comprehensive care.

Global Sickle Cell Disease Treatment Market: Segmentation Analysis

The Global Sickle Cell Disease Treatment Market is segmented based on Type, Drug Class, End-User, and Geography.

Sickle Cell Disease Treatment Market, By Type

  • Bone Marrow Transplant
  • Blood Transfusion

Based on Type, the Global Sickle Cell Disease Treatment Market is bifurcated into Bone Marrow Transplant and Blood Transfusion. The bone marrow transplant segment is dominant due to potential curative options for sickle cell disease (SCD), though it is limited by the availability of compatible donors. Blood Transfusion is a widely used treatment method, particularly for managing acute symptoms and preventing complications such as stroke and organ damage in SCD patients.

Sickle Cell Disease Treatment Market, By Drug Class

  • Hydroxyurea
  • L-glutamine
  • Voxelotor

Based on Drug Class, the Global Sickle Cell Disease Treatment Market is segmented into Hydroxyurea, L-glutamine, and Voxelotor. Hydroxyurea is the most commonly used medication for SCD, significantly reducing the frequency of painful episodes and the need for blood transfusions. Voxelotor and L-glutamine are newer drug therapies aimed at improving hemoglobin levels and reducing the severity of disease symptoms providing additional treatment options for patients.

Sickle Cell Disease Treatment Market, By End-User

  • Hospitals
  • Specialty Clinics

Based on the End-User, the Global Sickle Cell Disease Treatment Market is bifurcated into Hospitals and Specialty Clinics. Hospitals dominate the market as they provide comprehensive treatment options including blood transfusions, bone marrow transplants, and access to specialized medications. Specialty Clinics focus on long-term care management for SCD patients offering personalized treatment plans and outpatient care for ongoing monitoring.

Key Players

  • The Global Sickle Cell Disease Treatment Market study report provides valuable insights with an emphasis on the global market. The major players in the market include Global Blood Therapeutics, Inc., Novartis AG, Pfizer Inc., Emmaus Life Sciences, Inc., Bluebird Bio, Inc., Sangamo Therapeutics, Inc., and CRISPR Therapeutics AG.

Our market analysis also includes a section solely dedicated to these major players, offering insights into their financial statements, product benchmarking, and SWOT analysis. The competitive landscape section covers key development strategies, market share, and ranking analysis of the above-mentioned players globally.

Global Sickle Cell Disease Treatment Market Key Developments

  • In March 2024, Global Blood Therapeutics received FDA approval for its drug voxelotor, which is designed to improve hemoglobin levels and reduce complications in SCD patients.
  • In August 2024, Novartis announced positive results from its clinical trials of gene therapy for SCD, showing promising results in reducing the need for blood transfusions.
  • In October 2024, Bluebird Bio announced advancements in its gene-editing therapy using CRISPR technology, with early trials showing potential for curative treatment in SCD patients.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL SICKLE CELL DISEASE TREATMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL SICKLE CELL DISEASE TREATMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Bone Marrow Transplant
  • 5.3 Blood Transfusion

6 GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG CLASS

  • 6.1 Overview
  • 6.2 Hydroxyurea
  • 6.3 L-glutamine
  • 6.4 Voxelotor

7 GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Specialty Clinics

8 GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 France
    • 8.3.3 Spain
    • 8.3.4 Italy
    • 8.3.5 U.K.
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 South Korea
    • 8.4.5 Australia
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL SICKLE CELL DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Global Blood Therapeutics, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Novartis AG
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Pfizer Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Emmaus Life Sciences, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Bluebird Bio, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Sangamo Therapeutics, Inc.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 CRISPR Therapeutics AG.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research